Esteban-Fernandez, AlbertoOrtiz Cortes, CarolinaLopez-Fernandez, SilviaRecio Mayoral, AlejandroCamacho Jurado, Francisco JavierGomez Otero, InesMolina, MariaAlmenar Bonet, LuisLopez-Vilella, Raquel2023-05-032023-05-032022-05-08Esteban-Fernández A, Ortiz Cortés C, López-Fernández S, Recio Mayoral A, Camacho Jurado FJ, Gómez Otero I, et al. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life. ESC Heart Fail. 2022 Oct;9(5):3071-3078.http://hdl.handle.net/10668/21917Hyperkalaemia (HK) is common in heart failure (HF) patients, related to renal dysfunction and medical treatment. It limits medical therapy optimization, which impacts prognosis. New potassium (K) binders help control HK, allowing better medical management of HF. A retrospective multicentre register included all outpatients with HF and HK (K ≥ 5.1 mEq/L) treated with patiromer according to current recommendations. We evaluated analytic and clinical parameters before starting the treatment and at 7, 30 and 90 days, as well as adverse events related to patiromer and treatment optimization. We included 74 patients (71.6% male) with a mean age of 70.8 years (SD 9.2). Sixty-seven patients (90.5%) presented HK in the previous year. Forty patients (54.1%) underwent down-titration of a renin-angiotensin-aldosterone inhibitor (RAASi) or a mineralocorticoid receptor antagonist (MRA), and 27 (36.5%) stopped any of them due to HK. Initial K was 5.5 mEq/L (SD 0.6), with a significantly reduction at 7 days (4.9 mEq/L (SD 0.8); P  In a real-life cohort of patients with HF, patiromer reduced and maintained K levels during 3 months of follow-up. The most common adverse events were hypomagnesaemia and gastrointestinal disturbances. Patiromer helps optimize medical treatment, increasing the percentage of patients treated with RAASi and MRA at target doses. At the end of follow-up, natriuretic peptides values and hospital visits were reduced, suggesting the benefit of optimizing HF medical treatment.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttps://creativecommons.org/licenses/by-nc-nd/4.0/Heart failureHyperkalaemiaPatiromerPotassium bindersAgedFemaleHumansMaleHeart FailureHyperkalemiaMineralocorticoid Receptor AntagonistsPolymersPotassiumMiddle AgedAged, 80 and overresearch article35748119open accessAncianoAnciano de 80 o más añosAntagonistas de receptores de mineralocorticoidesFemeninoHiperpotasemiaHumanosInsuficiencia cardíacaMasculinoPersona de mediana edadPolímerosPotasio10.1002/ehf2.139762055-5822PMC9715760https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715760https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715760/pdf